Upfronts, milestones and tiered royalties valued from both sides of the table, and why a $325 million headline can be worth $61 million to the licensor.
Biotech licensing deals are announced at headline value: upfront plus every milestone, as if each one were certain to be paid. That number is useful for press releases and almost useless for decisions. What a licensor actually receives, and what a licensee actually pays, is the risked, after-tax present value of each payment, and the two sides rarely agree on it. This guide shows how to value a deal from both sides using two licences of Veltrana Therapeutics, a fictional biotech built as a teaching case: a proposed worldwide licence of its Phase 1 antibody VLT-305 to Marlowe Biosciences, announced at $325.00 million but worth $61.01 million to the licensor, and the existing ex-US licence of VLT-201 to Ostrander Pharma AG, with tiered royalties peaking at $47.30 million a year.
Worked in full in The Biotech Valuation Handbook by Julian R. Sterling, with every figure reproduced in live Excel workbooks.Get the DRM-free PDF, $19.99 →
Almost every licence combines the same four instruments, and each one has a different risk profile for the licensor.
Behind those instruments sit terms that rarely make the announcement but move value: who bears development and commercial costs, cost-sharing and opt-in rights, diligence obligations, reversion of rights if the licensee stops, and whether royalties step down or stop at generic entry. A model that captures the payments but ignores who pays the costs will get the deal wrong.
Headline value adds the payments at face value. Risked value multiplies each payment by the probability of its trigger, deducts tax, and discounts it to the valuation date. The difference is not a rounding issue: for an early-stage asset, risked value is typically a fraction of headline. The method is the same rNPV logic described in the guide on how to calculate rNPV step by step, applied to a stream of deal payments rather than to the asset's own sales.
The Veltrana case uses a valuation date of January 1, 2027, a discount rate of 11 percent for Veltrana, the mid-year convention, and tax of 21 percent on licence income.
VLT-305 is a bispecific antibody in Phase 1 for a biomarker-selected solid tumor. Developed alone, it has an rNPV of -$25.16 million: risked development costs of -$118.48 million against risked commercial cash flows of $93.31 million. The commercial opportunity is not the problem, since the unrisked NPV is $1,010.83 million. The problem is a cumulative probability of approval of 6.62 percent combined with Phase 3 spending of $140.00 million a year from 2031 to 2033.
Marlowe Biosciences proposes a worldwide licence:
| Payment | Trigger | Year | Amount ($m) |
|---|---|---|---|
| Upfront | Signing | 2027 | 40.00 |
| Development milestone | Phase 2 start | 2029 | 30.00 |
| Development milestone | Phase 3 start | 2031 | 60.00 |
| Regulatory milestone | Approval | 2035 | 120.00 |
| Sales milestone | US net sales reach $500 million | 2037 | 75.00 |
Royalties on US net sales are 8 percent up to $400 million, 11 percent from $400 million to $800 million and 14 percent above. Marlowe bears all costs. The headline deal value is 40 + 30 + 60 + 120 + 75 = $325.00 million.
Each payment is weighted by the probability of reaching its trigger, using the VLT-305 transition rates of 50 percent (Phase 1 to 2), 30 percent (Phase 2 to 3), 48 percent (Phase 3 to BLA) and 92 percent (BLA to approval). How those rates were set against the oncology benchmark is explained in the article on probability of success by clinical phase.
After 21 percent tax and discounting at 11 percent, the whole deal is worth $61.01 million to Veltrana. The upfront alone accounts for $29.99 million: 40.00 x (1 - 0.21) x 0.9492. Roughly half the risked value of a $325.00 million headline sits in the payment made at signing.
The comparison explains why licensors fight hardest over the upfront. A dollar of upfront is weighted at 100 percent with a discount factor of 0.9492. A dollar of approval milestone in 2035 is weighted at 6.62 percent with a factor of 0.4119, so it is worth about 0.027 of a dollar today. On a risked present value basis, one dollar at signing is worth more than thirty dollars of approval milestone. Headline value hides that completely.
A board should not compare the deal with zero; it should compare it with the alternative. Veltrana's alternative is to develop VLT-305 itself, worth -$25.16 million. The deal replaces that with $61.01 million, so out-licensing adds $86.17 million of value.
The gain has two sources. The visible one is the deal payments. The overlooked one is the cost avoided: Veltrana no longer carries risked development spend of -$118.48 million. In exchange it gives up risked commercial cash flows of $93.31 million. For a company whose success-path cash balance turns negative during 2030, avoiding the VLT-305 budgets matters beyond the valuation. At the company level, the deal lifts the sum-of-the-parts equity value from $325.15 million to $411.32 million, or from 5.61 to 7.09 dollars per share.
A deal that works for only one side does not get signed. Marlowe values the same asset differently for three reasons:
| View | Rate | Item | Value ($m) |
|---|---|---|---|
| Veltrana standalone | 11% | Asset rNPV | -25.16 |
| Veltrana as licensor | 11% | Deal value | 61.01 |
| Marlowe | 9% | Asset rNPV | 87.41 |
| Marlowe | 9% | Deal payments, PV after tax | 66.95 |
| Marlowe | 9% | Licensee NPV | 20.46 |
To Marlowe the asset is worth $87.41 million. The deal payments, deductible at 21 percent and discounted at its own 9 percent, cost it $66.95 million. Its net gain is 87.41 - 66.95 = $20.46 million. The licensee view keeps the case convention of no tax benefit on development costs, so a profitable licensee that deducts its R&D would see an even larger surplus.
The deal does not just transfer value; it creates it. The asset is worth more in Marlowe's hands than in Veltrana's because of worldwide rights, a lower cost of capital and an existing commercial organization. The term sheet splits that created value: Veltrana takes $86.17 million above its alternative and Marlowe keeps $20.46 million.
One subtlety: the same payment stream is worth $61.01 million to Veltrana but costs Marlowe $66.95 million. The difference, 66.95 - 61.01, about 5.9, comes from the discount rates. Because Marlowe discounts at a lower rate, every deferred payment weighs more as a liability in its books than as an asset in Veltrana's. On discount rates alone, both would gain from front-loading. Buyers still prefer back-loaded structures because they pay only on success. Whether the split is fair is a negotiation question; the valuation's job is to size the pie and show how each term moves the split. Building the counterparty's model, even roughly, tells you how much room you have before the deal breaks.
The VLT-201 ex-US licence to Ostrander Pharma AG shows how tiered royalties work. The upfront was received in 2025 and is sunk. What remains is $35.00 million on Phase 3 start in 2028, $50.00 million on EU approval in 2033, $40.00 million when annual ex-US net sales first reach $300.00 million (on forecast, in 2037), and royalties of 10 percent up to $150 million, 13 percent from $150 million to $300 million and 16 percent above.
Tiers apply in slices, like income tax brackets. At peak ex-US net sales of $380.00 million:
| Tier | Sales in tier ($m) | Rate | Royalty ($m) |
|---|---|---|---|
| Up to $150 million | 150 | 10% | 15.0 |
| $150 to $300 million | 150 | 13% | 19.5 |
| Above $300 million | 80 | 16% | 12.8 |
| Total | 380 | about 12.4% blended | 47.30 |
The peak royalty is $47.30 million a year, a blended rate of about 12.4 percent (47.30 / 380), well below the 16 percent top tier. Applying the top rate to total sales would overstate royalty income; applying the bottom rate would understate it. The tiers also explain why the royalty climbs faster than sales during the ramp: in 2033, ex-US sales of $45.60 million earn $4.56 million, exactly 10 percent; by 2037, sales of $342.00 million earn $41.22 million. After ex-US loss of exclusivity in 2045, the royalty falls to $9.50 million, then $3.80 million a year.
Each Ostrander payment is weighted by its trigger: the Phase 3 milestone at 35 percent, everything that needs approval at the 19.53 percent likelihood of approval. After tax and discounting, the remaining licence income is worth $32.92 million, one of three components of the VLT-201 rNPV of $71.09 million. That is far below the sum of the remaining milestones, because the two largest are weighted at 19.53 percent and discounted from 2033 and 2037. You can follow the royalty line year by year in the free rNPV drug asset valuation model.
The deal chapter of The Biotech Valuation Handbook covers negotiation levers in more depth: front-loading versus royalties, milestone triggers, tier thresholds, cost sharing, opt-ins and reversion.
Headline value adds the upfront and all milestones at face value. Risked value weights each payment by the probability of its trigger, deducts tax and discounts it. The Marlowe term sheet is $325.00 million headline but worth $61.01 million to the licensor, of which $29.99 million is the upfront.
Each rate applies only to the slice of annual net sales inside its tier, like tax brackets. At $380.00 million of ex-US sales, tiers of 10, 13 and 16 percent give 15.0 + 19.5 + 12.8 = $47.30 million, a blended rate near 12.4 percent rather than the 16 percent top rate.
When the asset is worth more to the licensee. Marlowe has worldwide rights, a 9 percent cost of capital and an existing sales force, so it values VLT-305 at $87.41 million against -$25.16 million for Veltrana alone. After paying $66.95 million in risked after-tax terms, Marlowe keeps $20.46 million while Veltrana gains $86.17 million over its alternative.
Its own. The licensor discounts deal receipts at its cost of capital and the licensee discounts deal payments at its own, usually lower, rate. Using one rate for both hides part of the negotiation. The free rNPV model lets you change the rate and see the effect.
This guide is one arc of The Biotech Valuation Handbook. The book values a whole clinical-stage company: probabilities of success, development costs, a patient-based peak sales forecast, gross-to-net, launch curves, exclusivity and the IRA, the asset cash flow, the discount rate, sensitivities, two licensing deals and the sum-of-the-parts.
Paperback PDF edition, $19.99 Book page and companion workbooks
Free download: rNPV Drug Asset Valuation Model (Excel).
Illustrative figures computed by the book's model; the company, its products and every dollar figure are fictional. Rules and benchmarks as read in November 2026; education only, not investment advice.